Wave Life Sciences ( NASDAQ: WVE ) announced that the U.S. FDA has granted Rare Pediatric Disease Designation to WVE-N531 for the treatment of boys with Duchenne muscular dystrophy who are amenable to exon 53 skipping.
WVE-N531 is currently being evaluated in the potentially registrational FORWARD-53 clinical trial and Wave expects to deliver data, including dystrophin protein expression from muscle biopsies after 24 weeks of treatment, in the third quarter of 2024. Source: Press Release More on Wave Life Sciences Wave Life Sciences Ltd. (WVE) Q2 2024 Earnings Call Transcript Wave Life Sciences Q2 2024 Earnings Preview Wave jumps on trial data for Huntington’s disease therapy Seeking Alpha’s Quant Rating on Wave Life Sciences Historical earnings data for Wave Life Sciences.
